Multiple Myeloma SPORE
Multiple myeloma is a clonal plasma cell malignancy, which, despite recent treatment advances, remains incurable in the vast majority of the more than 59,000 patients in the United States afflicted with this disease. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of patients with multiple myeloma. The SPORE in Multiple Myeloma is a multidisciplinary collaboration between investigators from The University of Texas MD Anderson Cancer Center (MD Anderson), the University of Pennsylvania (Penn), and Virginia Commonwealth University (VCU), who are pursing four highly innovative Projects:
- Project 1 – Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Qazilbash/June/Stadtmauer)
- Project 2 – Chemokine-Idiotype DNA Fusion Vaccines as a Therapeutic Anti-Tumor Strategy for Lymphoplasmacytic Lymphoma (Thomas/Neelapu)
- Project 3 – Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber)
- Project 4 – Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent)
To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities:
- Core A – Administrative Core Facility
- Core B – Myeloma Tissue Core Facility
- Core C – Animal Models Core Facility
- Core D – Clinical Trials Core Facility
- Core E – Biostatistics and Bioinformatics Core Facility
The SPORE will attract new investigators with additional novel ideas and train the next generation of myeloma researchers through the Developmental Research Program and the Career Development Program.
The SPORE will serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.